GlassScriptPhysician profile
Andrew R Clark
NPI 1912988635
$5,609.70
in general payments reported to CMS, 2019-2025
33 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $169 · 2021: $769 · 2022: $475 · 2023: $1,263 · 2024: $1,173 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $924.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $747.27 | 2019-2025 | |
| Abbvie INC. | $525.21 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Ormco Corporation | $507.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $475.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $337.77 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $321.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $266.72 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $244.97 | 2023-2025 | |
| Amgen INC. | $215.64 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $176.94 | 2019-2025 | Veozah |
| Smith+Nephew, INC. | $98.60 | 2023 | Renasys Touch, Pico |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.59 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $69.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $61.71 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.50 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $54.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $49.25 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.23 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $42.56 | 2019 | |
| Abbott Laboratories | $34.79 | 2023-2024 | Proclaim |
| Ferring Pharmaceuticals INC. | $31.57 | 2022-2023 | Euflexxa |
| Amarin Pharma, INC. | $31.09 | 2019 | |
| Insmed, INC. | $26.20 | 2025 | Arikayce |
| Allergan, INC. | $24.48 | 2020 | |
| Radius Health, INC. | $23.92 | 2025 | Tymlos |
| Corium, LLC | $20.49 | 2023 | Azstarys |
| Tris Pharma INC | $19.45 | 2025 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $19.14 | 2024 | Voquezna |
| Viatris Specialty LLC | $15.83 | 2025 | Yupelri |
| Ibsa Pharma INC. | $14.85 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.